EE04796B1 - Fumaarhappe mikrotabletid - Google Patents

Fumaarhappe mikrotabletid

Info

Publication number
EE04796B1
EE04796B1 EEP200100030A EEP200100030A EE04796B1 EE 04796 B1 EE04796 B1 EE 04796B1 EE P200100030 A EEP200100030 A EE P200100030A EE P200100030 A EEP200100030 A EE P200100030A EE 04796 B1 EE04796 B1 EE 04796B1
Authority
EE
Estonia
Prior art keywords
micro
tablets
fumaric acid
cation
series
Prior art date
Application number
EEP200100030A
Other languages
English (en)
Estonian (et)
Inventor
Kumar Joshi Rajendra
Strebel Hans-Peter
Original Assignee
Fumapharm Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fumapharm Ag filed Critical Fumapharm Ag
Publication of EE200100030A publication Critical patent/EE200100030A/xx
Publication of EE04796B1 publication Critical patent/EE04796B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Soft Magnetic Materials (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
EEP200100030A 1998-10-20 1999-10-08 Fumaarhappe mikrotabletid EE04796B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19848260A DE19848260C2 (de) 1998-10-20 1998-10-20 Fumarsäure-Mikrotabletten
PCT/EP1999/007568 WO2000023068A2 (de) 1998-10-20 1999-10-08 Fumarsäure-mikrotabletten

Publications (2)

Publication Number Publication Date
EE200100030A EE200100030A (et) 2002-06-17
EE04796B1 true EE04796B1 (et) 2007-04-16

Family

ID=7885018

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100030A EE04796B1 (et) 1998-10-20 1999-10-08 Fumaarhappe mikrotabletid

Country Status (27)

Country Link
US (1) US6355676B1 (zh)
EP (1) EP1123092B1 (zh)
JP (1) JP3550091B2 (zh)
CN (1) CN1235578C (zh)
AT (1) ATE222760T1 (zh)
AU (1) AU745889B2 (zh)
BG (1) BG64836B1 (zh)
BR (1) BR9910267A (zh)
CA (1) CA2329543C (zh)
CZ (1) CZ300005B6 (zh)
DE (2) DE19848260C2 (zh)
DK (1) DK1123092T3 (zh)
EE (1) EE04796B1 (zh)
ES (1) ES2182568T3 (zh)
HK (1) HK1041216B (zh)
HU (1) HU229384B1 (zh)
IL (1) IL140891A (zh)
MX (1) MXPA01003966A (zh)
NO (1) NO328720B1 (zh)
NZ (1) NZ508065A (zh)
PL (1) PL193119B1 (zh)
PT (1) PT1123092E (zh)
RS (1) RS49775B (zh)
RU (1) RU2210366C2 (zh)
SK (1) SK286191B6 (zh)
TR (1) TR200003505T2 (zh)
WO (1) WO2000023068A2 (zh)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19853487A1 (de) 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
US20020044962A1 (en) * 2000-06-06 2002-04-18 Cherukuri S. Rao Encapsulation products for controlled or extended release
DE10101307A1 (de) * 2001-01-12 2002-08-01 Fumapharm Ag Muri Fumarsäurederivate als NF-kappaB-Inhibitor
ATE447945T1 (de) * 2001-01-12 2009-11-15 Biogen Idec Internat Gmbh Verwendung von fumarsäureamiden
US6613800B1 (en) * 2001-12-03 2003-09-02 Steven A. Smith Method and compositions for treating psoriasis, eczema, seborrhea and arthritis
DE10217314A1 (de) 2002-04-18 2003-11-13 Fumapharm Ag Muri Carbocyclische und Oxacarboncyclische Fumarsäure-Oligomere
SI1663197T1 (sl) * 2003-09-09 2008-06-30 Biogen Idec Internat Gmbh Uporaba derivatov fumarne kisline za zdravljenje sräśne insuficience in astme
PT2801355E (pt) * 2004-10-08 2015-09-18 Forward Pharma As Composições farmacêuticas de libertação controlada compreendendo um éster de ácido fumárico
US20080004344A1 (en) * 2004-11-10 2008-01-03 Aditech Pharma Ab Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use
ITBO20050123A1 (it) * 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
WO2007006308A1 (en) * 2005-07-07 2007-01-18 Aditech Pharma Ab Novel glucopyranose esters and glucofuranose esters of alkyl- fu marates and their pharmaceutical use
WO2007006307A2 (en) * 2005-07-07 2007-01-18 Aditech Pharma Ab Novel salts of fumaric acid monoalkylesters and their pharmaceutical use
PT1762231E (pt) * 2005-08-19 2010-12-13 Verla Pharm Microcomprimidos de magnésio de libertação retardada
WO2007042034A1 (en) * 2005-10-07 2007-04-19 Aditech Pharma Ab Controlled release pharmaceutical compositions comprising a fumaric acid ester
WO2007042035A2 (en) * 2005-10-07 2007-04-19 Aditech Pharma Ab Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
ES2599227T3 (es) * 2007-02-08 2017-01-31 Biogen Ma Inc. Neuroprotección en enfermedades desmielinizantes
ES2916604T1 (es) 2007-02-08 2022-07-04 Biogen Ma Inc Ensayos de detección de nrf2 y métodos y composiciones relacionados
PL2334378T3 (pl) 2008-08-19 2014-09-30 Xenoport Inc Proleki wodorofumaranu metylu, ich kompozycje farmaceutyczne i sposoby zastosowania
EP2564839B1 (en) 2009-01-09 2016-05-11 Forward Pharma A/S Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
PL2718257T3 (pl) 2011-06-08 2018-04-30 Biogen Ma Inc. Sposób przygotowywania dimetylofumaranu krystalicznego o wysokiej czystości
WO2013076216A1 (en) 2011-11-24 2013-05-30 Synthon Bv Controlled release particles comprising dimethyl fumarate
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
CN114146079A (zh) 2012-02-07 2022-03-08 比奥根玛公司 含有富马酸二甲酯的药物组合物
MX2014009511A (es) 2012-02-07 2014-10-24 Xenoport Inc Compuestos de fumarato de morfolinoalquilo, composiciones farmaceuticas y metodos de uso.
JP2015526477A (ja) 2012-08-22 2015-09-10 ゼノポート，インコーポレイティド メチル水素フマレートの経口剤形およびそのプロドラッグ
US10945984B2 (en) 2012-08-22 2021-03-16 Arbor Pharmaceuticals, Llc Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
US20140171504A1 (en) * 2012-12-14 2014-06-19 Georgia Regents Research Institute, Inc. Methods of Treating Sickle Cell Disease and Related Disorders Using Fumaric Acid Esters
AR094277A1 (es) 2012-12-21 2015-07-22 Biogen Idec Inc Derivados de fumarato sustituidos con deuterio
SG11201507371RA (en) 2013-03-14 2015-10-29 Alkermes Pharma Ireland Ltd Prodrugs of fumarates and their use in treating various deseases
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
US10179118B2 (en) 2013-03-24 2019-01-15 Arbor Pharmaceuticals, Llc Pharmaceutical compositions of dimethyl fumarate
WO2014197860A1 (en) 2013-06-07 2014-12-11 Xenoport, Inc. Method of making monomethyl fumarate
WO2014205392A1 (en) 2013-06-21 2014-12-24 Xenoport, Inc. Cocrystals of dimethyl fumarate
EA201690102A1 (ru) 2013-08-26 2016-06-30 Форвард Фарма А/С Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе
US9416096B2 (en) 2013-09-06 2016-08-16 Xenoport, Inc. Crystalline forms of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, methods of synthesis and use
WO2015042294A1 (en) 2013-09-18 2015-03-26 Xenoport, Inc. Nanoparticle compositions of dimethyl fumarate
BR112016012179B1 (pt) 2013-12-12 2023-04-18 Almirall, S.A. Composições farmacêuticas que compreendem fumarato de dimetila
CA2940845C (en) 2014-02-24 2019-09-24 Alkermes Pharma Ireland Limited Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
EP3110408B1 (en) 2014-02-28 2019-01-16 Banner Life Sciences LLC Controlled release enteric soft capsules of fumarate esters
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
WO2016061393A1 (en) 2014-10-15 2016-04-21 Xenoport, Inc. Fumarate compounds, pharmaceutical compositions, and methods of use
CN104490849A (zh) * 2014-11-24 2015-04-08 广东东阳光药业有限公司 一种高密度的富马酸二甲酯肠溶颗粒及其制备方法
US10213411B2 (en) 2015-08-27 2019-02-26 Vijaykumar Rajasekhar Use of prodrugs of fumarates in treating heart failure diseases
WO2017060420A1 (en) 2015-10-07 2017-04-13 Neurovive Pharmaceutical Ab Protected fumaric acid-based metabolites for the treatment of autoimmune diseases
US10463642B2 (en) 2016-02-01 2019-11-05 Vijaykumar Rajasekhar Methods of treating heart failure diseases using prodrugs of methyl hydrogen fumarate
WO2020094767A1 (en) 2018-11-08 2020-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of nrf2 activators for the treatment of staphylococcus aureus infections
BR112021018452B1 (pt) 2019-05-31 2022-10-04 Curacle Co., Ltd Comprimido de revestimento entérico e seu método de preparação
CN110898164A (zh) * 2019-12-19 2020-03-24 赣州安宏环保科技有限公司 根除胃肠病幽门螺杆菌感染的富马酸单乙酯钙盐及其用途
US11903918B2 (en) 2020-01-10 2024-02-20 Banner Life Sciences Llc Fumarate ester dosage forms with enhanced gastrointestinal tolerability
KR20220133807A (ko) 2021-03-25 2022-10-05 주식회사 큐라클 특정 약동학적 매개변수를 나타내는 디메틸푸마레이트를 유효성분으로 함유한 약학적 조성물
WO2024047248A1 (en) 2022-09-02 2024-03-07 Institut National de la Santé et de la Recherche Médicale Use of nrf2 activators for the treatment of cerebral small vessel disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2530372A1 (de) * 1975-07-08 1977-01-13 Walter Dr Schweckendiek Pharmazeutische zubereitungen zur behandlung von psoriasis
DE2621214C3 (de) * 1976-05-13 1981-11-12 Koronis Gmbh Chemisch-Pharmazeutische Praeparate, 5441 Sassen Verwendung von Stabilisatoren in Arzneimitteln mit Fumarsäuremonoäthylester und desen Mineralsalzen
US5149695A (en) * 1985-01-15 1992-09-22 Speiser Peter P Fumaric acid derivatives, process for the production thereof and pharmaceutical compositions containing same
CH664150A5 (de) 1985-01-15 1988-02-15 Peter Paul Prof Dr Speiser Fumarsaeureprodrug, verfahren zu seiner herstellung und dieses enthaltende darreichungsformen.
US4959389A (en) 1987-10-19 1990-09-25 Speiser Peter P Pharmaceutical preparation for the treatment of psoriatic arthritis
US5424332A (en) * 1987-10-19 1995-06-13 Speiser; Peter P. Pharmaceutical composition and process for the production thereof
DE3834794A1 (de) * 1988-10-12 1990-04-19 F Schielein Oral zu verabreichendes mittel zur behandlung von psoriasis
DE19721099C2 (de) * 1997-05-20 1999-12-02 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten

Also Published As

Publication number Publication date
CA2329543C (en) 2007-02-06
SK5392001A3 (en) 2001-08-06
NO328720B1 (no) 2010-05-03
AU6090699A (en) 2000-05-08
PL193119B1 (pl) 2007-01-31
HK1041216A1 (en) 2002-07-05
ES2182568T3 (es) 2003-03-01
DE19848260C2 (de) 2002-01-17
MXPA01003966A (es) 2002-08-20
HK1041216B (zh) 2006-06-30
ATE222760T1 (de) 2002-09-15
HU229384B1 (en) 2013-11-28
BG64836B1 (bg) 2006-06-30
HUP0103999A2 (hu) 2002-02-28
CN1235578C (zh) 2006-01-11
EE200100030A (et) 2002-06-17
DE19848260A1 (de) 2000-05-18
CA2329543A1 (en) 2000-04-27
NZ508065A (en) 2003-08-29
NO20005239D0 (no) 2000-10-18
DE59902490D1 (de) 2002-10-02
BG104836A (en) 2001-04-30
HUP0103999A3 (en) 2003-11-28
CZ300005B6 (cs) 2009-01-14
SK286191B6 (sk) 2008-05-06
JP3550091B2 (ja) 2004-08-04
RU2210366C2 (ru) 2003-08-20
IL140891A (en) 2005-09-25
WO2000023068A2 (de) 2000-04-27
IL140891A0 (en) 2002-02-10
CZ2001871A3 (cs) 2001-07-11
RS49775B (sr) 2008-06-05
BR9910267A (pt) 2001-01-09
TR200003505T2 (tr) 2001-07-23
EP1123092B1 (de) 2002-08-28
YU65500A (sh) 2002-09-19
NO20005239L (no) 2001-05-21
PT1123092E (pt) 2003-01-31
JP2002527475A (ja) 2002-08-27
US6355676B1 (en) 2002-03-12
WO2000023068A3 (de) 2000-07-27
PL344528A1 (en) 2001-11-05
CN1323206A (zh) 2001-11-21
DK1123092T3 (da) 2002-10-14
AU745889B2 (en) 2002-04-11
EP1123092A2 (de) 2001-08-16

Similar Documents

Publication Publication Date Title
DK1123092T3 (da) Fumarsyre-mikrotabletter
EE200000440A (et) Fumaarhappe derivaatide kasutamine
HK1027512A1 (en) The use of fumaric acid derivatives.
ES8406075A1 (es) Un procedimiento para la preparacion de una sal de adicion de un acido bencenosulfonico de la sultamicilina.
HUT52374A (en) Process for producing pharmaceutical compositions
IL75852A (en) Pharmaceutical composition containing pyrimido-pyrimidines and o-acetylsalicyclic acid or its pharmacologically tolerated salts
DE69100954D1 (de) Lagerstabile orale Glucosaminsulfat-Dosisformen und Verfahren zu deren Herstellung.
ZA853715B (en) 3,17 beta-estriol diesters,processes for their production,and pharmaceutical preparations containing them
IL88011A0 (en) Pharmaceutical preparation for the treatment of psoriasis,psoriatic arthritis,neurodermatitis and enteritis regionalis crohn comprising fumaric acid salts
IT1242026B (it) Composizione farmaceutica contenente un complesso ferro-schizokinene per il trattamento dell'anemia ferropenica.

Legal Events

Date Code Title Description
HE1A Change of address
KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231

GB1A Change in the ownership or in the address of the owner
HD1A Correction of address
MM4A Lapsed by not paying the annual fees

Effective date: 20161008